Clinical Trial Update: Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer [Phase 2]

View source ↗

Summary

This update reports the completed Phase 2 safety and efficacy study of the PSMA-targeted fluorescent contrast agent DGPR1008 for intraoperative imaging of prost…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DGPR1008

Snippet

Sponsor: Haitao Niu, MD | Conditions: Prostate Cancer Patients Undergoing Radical Prostatectomy | Phase 2 | Status: COMPLETED